Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	13,117	12,173	16,072	8,497	6,558
Revenue Growth (YoY)	7.76%	-24.26%	89.14%	29.58%	27.44%
Cost of Revenue	1,816	1,560	2,438	1,120	765.1
Gross Profit	11,301	10,613	13,634	7,377	5,793
Selling, General & Admin	2,631	2,116	1,825	1,346	1,342
Research & Development	4,439	3,593	2,860	2,647	2,450
Other Operating Expenses	184	165.2	2.4	-192.4	-209.2
Operating Expenses	7,254	5,874	4,687	3,801	3,583
Operating Income	4,047	4,739	8,947	3,577	2,210
Interest Expense / Income	73	59.4	57.3	56.9	30.2
Other Expense / Income	-225.2	-179.3	-436.3	-290.7	-249.5
Pretax Income	4,199	4,859	9,326	3,810	2,429
Income Tax	245.7	520.4	1,251	297.2	313.3
Net Income	3,954	4,338	8,075	3,513	2,116
Net Income Growth	-8.87%	-46.28%	129.86%	66.05%	-13.44%
Shares Outstanding (Basic)	107	107	106	108	109
Shares Outstanding (Diluted)	114	114	112	115	115
Shares Change	0.18%	1.16%	-2.52%	0.44%	-0.17%
EPS (Basic)	37.05	40.51	76.40	32.65	19.38
EPS (Diluted)	34.77	38.22	71.97	30.52	18.46
EPS Growth	-9.03%	-46.89%	135.81%	65.33%	-13.29%
Free Cash Flow	3,875	4,425	6,529	2,004	2,000
Free Cash Flow Per Share	36.32	41.31	61.77	18.62	18.32
Gross Margin	86.16%	87.18%	84.83%	86.82%	88.33%
Operating Margin	30.85%	38.93%	55.67%	42.09%	33.70%
Profit Margin	30.14%	35.64%	50.25%	41.35%	32.26%
Free Cash Flow Margin	29.54%	36.35%	40.63%	23.58%	30.51%
Effective Tax Rate	5.85%	10.71%	13.41%	7.80%	12.90%
EBITDA	4,693	5,260	9,669	4,103	2,670
EBITDA Margin	35.78%	43.21%	60.16%	48.29%	40.71%
Depreciation & Amortization	421	341.4	286.2	235.9	210.3
EBIT	4,272	4,918	9,383	3,867	2,459
EBIT Margin	32.57%	40.40%	58.38%	45.51%	37.50%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).